Statement from IPA on Biomarin

For Immediate Release July 4, 2016 As the International Pompe Association (IPA) has previously announced, on Thursday, June...
Author: IPA
Archive
July 4, 2016

BioMarin Update for the Pompe Community

The IPA Board was provided with the following statement regarding Biomarin's BMN-701 study. If you have any questions...
Author: Biomarin
Archive
June 22, 2016

IPA Statement on Biomarin’s June 9th announcement it will seek to out-license BMN-701

Since it was founded in 1999, the International Pompe Association (IPA) has worked directly with the different industry...
Author: Tiffany House
Archive
June 15, 2016

The Walker Society – a beneficiary research fund in honour of Helen Walker

My sister, Helen Walker was diagnosed in 1990 with Pompe’s Disease. Little was known about this rare disease...
Author: Bruce Walker, brother of Helen Walker
Archive
May 10, 2016

Press Release: International Pompe Day 2016 – Early Diagnosis

Download this Press Release (PDF, 475 kB) For Immediate Release April 15, 2016 will be the Third Annual...
Author: Webmaster
Archive
April 14, 2016

Celebrating the Pompe Disease Community

Also celebrating 10 years of treatment and International Pompe Day 2016… {youtube}LYiq4nc3qcs|427|240{/youtube} Link to the video on YouTube...
Author: Genzyme & IPA
Archive
April 14, 2016

2016 International Pompe Day Art Contest “Together We Are Strong”

Official Rules Art Contest Entry Form Deadline for Submissions: April 8, 2016 Qualified Participants The 2016 International Pompe...
Author: IPA
Archive
March 22, 2016

Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe Disease

Results support beginning pivotal Phase 3 clinical trial in Q2 2016 Sanofi and its specialty care global business...
Author: Genzyme
Archive
March 2, 2016

BioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease at 34th Annual J.P. Morgan Annual Healthcare Conference

Reveglucosidase Alfa Trends Positive in Respiratory Muscle Strength and Endurance Endpoints in Patients Previously Treated With Enzyme Replacement...
Author: Biomarin
Archive
January 10, 2016

Amicus Therapeutics Commences Phase 1/2 Study of Novel ERT for Treatment of Pompe Disease

Amicus Therapeutics Commences Phase 1/2 Study of Novel ERT for Treatment of Pompe Disease CRANBURY, N.J., Dec. 22,...
Author: Amicus
Archive
December 21, 2015
1 … 4 5 6 7 8 … 38